Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Assessing biases of information contained in pedigrees for the classification of BRCA-genetic variants: a study arising from the ENIGMA analytical working group.

Kerkhofs CH, Spurdle AB, Lindsey PJ, Goldgar DE, Gómez-García EB.

Hered Cancer Clin Pract. 2016 Apr 30;14:10. doi: 10.1186/s13053-016-0050-9. eCollection 2016.

2.

Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.

Robinson LS, Hendrix A, Xie XJ, Yan J, Pirzadeh-Miller S, Pritzlaff M, Read P, Pass S, Euhus D, Ross TS.

EBioMedicine. 2015 Oct 21;2(11):1827-33. doi: 10.1016/j.ebiom.2015.10.022. eCollection 2015 Nov.

3.

UK BRCA mutation testing in patients with ovarian cancer.

George A.

Br J Cancer. 2015 Dec 15;113 Suppl 1:S17-21. doi: 10.1038/bjc.2015.396. Review.

PMID:
26669451
4.

BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.

Høberg-Vetti H, Bjorvatn C, Fiane BE, Aas T, Woie K, Espelid H, Rusken T, Eikesdal HP, Listøl W, Haavind MT, Knappskog PM, Haukanes BI, Steen VM, Hoogerbrugge N.

Eur J Hum Genet. 2016 Jun;24(6):881-8. doi: 10.1038/ejhg.2015.196. Epub 2015 Sep 9.

5.

A clinical and genetic analysis of multiple primary cancer referrals to genetics services.

Whitworth J, Hoffman J, Chapman C, Ong KR, Lalloo F, Evans DG, Maher ER.

Eur J Hum Genet. 2015 May;23(5):581-7. doi: 10.1038/ejhg.2014.157. Epub 2014 Sep 24.

6.

Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population.

van den Broek AJ, de Ruiter K, van 't Veer LJ, Tollenaar RA, van Leeuwen FE, Verhoef S, Schmidt MK.

Eur J Hum Genet. 2015 May;23(5):588-95. doi: 10.1038/ejhg.2014.161. Epub 2014 Aug 20.

7.

Clinical prediction rules in practice: review of clinical guidelines and survey of GPs.

Plüddemann A, Wallace E, Bankhead C, Keogh C, Van der Windt D, Lasserson D, Galvin R, Moschetti I, Kearley K, O'Brien K, Sanders S, Mallett S, Malanda U, Thompson M, Fahey T, Stevens R.

Br J Gen Pract. 2014 Apr;64(621):e233-42. doi: 10.3399/bjgp14X677860. Review.

8.

Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer.

Kim H, Choi DH.

J Breast Cancer. 2013 Dec;16(4):357-65. doi: 10.4048/jbc.2013.16.4.357. Epub 2013 Dec 31. Review.

9.

BRCA sequencing and large rearrangement testing in young Black women with breast cancer.

Pal T, Bonner D, Cragun D, Johnson S, Akbari M, Servais L, Narod S, Vadaparampil S.

J Community Genet. 2014 Apr;5(2):157-65. doi: 10.1007/s12687-013-0166-9. Epub 2013 Aug 29.

10.

The application of nonsense-mediated mRNA decay inhibition to the identification of breast cancer susceptibility genes.

Johnson JK, Waddell N; kConFab Investigators, Chenevix-Trench G.

BMC Cancer. 2012 Jun 15;12:246. doi: 10.1186/1471-2407-12-246.

11.

Efficient identification and referral of low-income women at high risk for hereditary breast cancer: a practice-based approach.

Joseph G, Kaplan C, Luce J, Lee R, Stewart S, Guerra C, Pasick R.

Public Health Genomics. 2012;15(3-4):172-80. doi: 10.1159/000336419. Epub 2012 Apr 4. Erratum in: Public Health Genomics. 2015;18(1):65-6.

12.

Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.

Kwong A, Wong CH, Suen DT, Co M, Kurian AW, West DW, Ford JM.

World J Surg. 2012 Apr;36(4):702-13. doi: 10.1007/s00268-011-1406-y.

13.

Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.

Gadzicki D, Evans DG, Harris H, Julian-Reynier C, Nippert I, Schmidtke J, Tibben A, van Asperen CJ, Schlegelberger B.

J Community Genet. 2011 Jun;2(2):53-69. doi: 10.1007/s12687-011-0042-4. Epub 2011 Mar 2.

14.

BRCA1/2 mutations and triple negative breast cancers.

Peshkin BN, Alabek ML, Isaacs C.

Breast Dis. 2010;32(1-2):25-33. doi: 10.3233/BD-2010-0306. Review.

15.

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.

Evans DG, Moran A, Hartley R, Dawson J, Bulman B, Knox F, Howell A, Lalloo F.

Br J Cancer. 2010 Mar 30;102(7):1091-8. doi: 10.1038/sj.bjc.6605606. Epub 2010 Mar 16.

16.

Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection.

van Harssel JJ, van Roozendaal CE, Detisch Y, Brandão RD, Paulussen AD, Zeegers M, Blok MJ, Gómez García EB.

Fam Cancer. 2010 Jun;9(2):193-201. doi: 10.1007/s10689-009-9305-1.

17.

Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer.

Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe M, Herte B, McKay-Chopin S, Thomas A, Vallée MP, Voegele C, Webb PM, Whiteman DC; Australian Cancer Study; Breast Cancer Family Registries (BCFR); Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab), Sangrajrang S, Hopper JL, Southey MC, Andrulis IL, John EM, Chenevix-Trench G.

Am J Hum Genet. 2009 Oct;85(4):427-46. doi: 10.1016/j.ajhg.2009.08.018. Epub 2009 Sep 24.

18.

Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.

Kurian AW, Gong GD, John EM, Miron A, Felberg A, Phipps AI, West DW, Whittemore AS.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1084-91. doi: 10.1158/1055-9965.EPI-08-1090. Epub 2009 Mar 31.

19.

Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States.

Huo D, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, Hope K, Olopade OI.

J Clin Oncol. 2009 Mar 10;27(8):1184-90. doi: 10.1200/JCO.2008.17.5869. Epub 2009 Feb 2. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262.

20.

Selecting a BRCA risk assessment model for use in a familial cancer clinic.

Panchal SM, Ennis M, Canon S, Bordeleau LJ.

BMC Med Genet. 2008 Dec 22;9:116. doi: 10.1186/1471-2350-9-116.

Items per page

Supplemental Content

Write to the Help Desk